国际皮肤性病学杂志    2004 30 (3): 200-202   ISSN: 2096-5540  CN: 32-1880/R   艾滋病相关型Kaposi肉瘤治疗进展 刘国艳1, 徐秀莲2, 孙建方2 1. 山东省潍坊市皮肤病防治所 261041; 2. 中国医学科学院、中国协和医科大学皮肤病研究所 收稿日期 2003-08-26  修回日期 null  网络版发布日期 null 参考文献  [1] Lebbe C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS, 1998, 12:F45-49. [2] Dupin N, Rubin De Cervens V, Gorin I, et al. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma.Br J Dermatol, 1999, 140:875-881. [3] Dupont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l′immunodeficience humaine. AIDS, 2000, 14:987-993. [4] Northfelt DW, Dezube B J, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase Ⅲ clinical trial. J Clin Oncol, 1998, 16:2445-2451. [5] Welles L, Saville MW, lietzau J,et al. Phase Ⅱ trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol, 1998, 16:1112. [6] Dezube BJ, Von Roenn JH, Holen-Wiltse J,et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol, 1998, I: 1444-1449. [7] Eckhardt SG, Burris HA, Eckardt JR, et al. A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol, 1996, 7:491-496. [8] Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol, 2000, 18:2593. [9] Tulpule A, Scadden DT, Espina BM, et al. Results of a randomized tudy of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol, 2000, 18:716-723. [10] Miles SA, Dezube BJ, Lee JY, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS, 2002,16:421-429. [11] Duvic M, Friedman-Kien AE, Looney DJ, et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials.Arch Dermatol, 2000, 136:1461-1469. [12] Gill PS, McLaughlin T, Espina BM, et al. Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi's sarcoma.J Natl Cancer Inst, 1997, 89:1797-1802. [13] Glesby M J, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis, 1996, 173:1477-1480. [14] Mocroft A, Youle M, Gazzard B, et al. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS, 1996, 10:1101-1105. 通讯作者: